A growing and aging world population and the increasing strain on nature’s ecosystems are among humanity’s most profound challenges – and solving them will demand a regular cadence of applied innovation.
For over 160 years, Bayer has been committed to innovative scientific research and development to solve some of the most pressing global challenges in healthcare and agriculture. As a global leader in Life Sciences, Bayer always focuses on customer-centric strategies for farmers and patients - guided by its mission “Health for all, Hunger for none”.
A fundamental element of the partnership with Bayer is Capgemini's commitment to investing in applied innovation to advance Bayer's initiatives. The result is an AIE (Applied Innovation Exchange) dedicated exclusively to Bayer – the first of its kind.
Since its formation in 2021, the Dedicated AIE Bayer has completed 13 innovation projects that are in productive use, with further 22 initiatives still being in experimentation or implementation phase.
Innovation in action
Through our AIE we jointly explore opportunities to apply emerging technologies with Bayer. One focus area is AI (Artificial Intelligence) and Generative AI. Together, AI and ML (Machine Learning) are being used for predictive maintenance, to reduce maintenance costs and improve sustainability; and for in silico (computer simulated) shelf-life testing to reduce costs, accelerate time to market and deliver practical solutions for business growth.
At the same time, generative AI is playing an increasingly important role in pharmaceutical research and development, where it will help to make clinical trials more effective. The innovation fund is de-risking and accelerating applied innovation to unlock value throughout Bayer.
